What to Know About the CFO of Tempus AI's Latest Insider Transaction Filing

Tempus AI's CFO, James William Rogers, sold 48,842 shares of the company's Class A Common Stock on August 18 and 19, as revealed in a recent SEC Form 4 filing. The transaction value, calculated using the SEC Form 4 weighted average sale price of $55.21, amounted to $2.85 million. The post-transaction value, based on the August 19 market close at $61.25, was $2.99 million.

The sale was a non-discretionary transaction aimed at fulfilling tax withholding obligations arising from the vesting of restricted stock units. This action was executed under a pre-existing Rule 10b5-1 trading plan adopted on September 11, 2025, and does not signify a shift in the CFO's fundamental opinion on the company.

Following the sale, James William Rogers now holds 106,000 shares, representing an insider ownership stake of approximately 0.06% of the company's outstanding equity. As of the August 19 transaction date, the stock's one-year total return stood at -16%. The transaction was conducted at a weighted-average price of $55.21 per share, while the stock closed at $61.25 on August 19.

Tempus AI operates in the healthcare information services sector with around 3,800 employees. The company reported trailing twelve-month revenue of $1.4 billion and experienced a net loss of $254.4 million. Tempus AI's market capitalization is currently valued at $10.7 billion. The company offers a technology-enabled laboratory services model that combines next-generation sequencing (NGS) testing with AI-driven analytics to provide actionable clinical insights to healthcare providers, focusing on oncology and precision medicine applications.

The full-stack healthcare technology platform integrates clinician workflows with laboratory diagnostic capabilities.

Despite the recent share sale, Tempus AI's long-term prospects remain positive. The company employs a technology-driven laboratory services model that differentiates it from competitors, with a proprietary multimodal data repository and closed-loop integration between clinician workflows and laboratory capabilities. This positions Tempus AI as a comprehensive solution provider in precision medicine, attracting significant market interest despite its current net losses.

The CFO's sale appears to adhere to an established 10b5-1 plan structure, executed on both August 18 and 19.